New Study for K-Ras Stage IV : Enroll THIS WEEK!

dianetavegia Member Posts: 1,942
edited March 2014 in Colorectal Cancer #1
Click Here for full article

The open-label, 56-patient KRAS-mutated colorectal cancer study is being conducted at three U.S. locations. Patient enrollment begins this week. All subjects will receive Imprime PGG® at 4 mg/kg weekly plus standard doses of Erbitux®. Tumor measurements and determination of tumor responses for this study will be performed according to Response Evaluation Criteria in Solid Tumors (RECIST).